AGN fundamentals
Key facts
Market capitalization—
Founded—
CEO—
Website—
About
Argenica Therapeutics Ltd. provides neuroprotective treatment. It specializes in development and commercialization of a novel therapeutic known as ARG-007. It offers drug ARG-007 in multiple models of stroke and other central nervous system (CNS) injury models, specifically: stroke including non-human primates; traumatic brain injury; and perinatal hypoxia ischaemia. The company was founded on 20 November 2019 and is headquartered in Nedlands, Australia.
Valuation
Fundamental metrics to determine fair value of the stock
Growth and Profitability
Company’s recent performance and margins
Dividends
Dividend yield, history and sustainability
AGN does not pay dividends
The company has not previously paid dividends and at the moment there is no information about whether it is going to pay them in the future
Financial health
Financial position and solvency of the company